Sumatriptan and Naproxen to Treat Migraine in Adolescents
Sumatriptan and Naproxen to Treat Migraine in Adolescents
Sumatriptan is contraindicated in patients who have received ergotamine-containing drugs, such as dihydroergotamine or methysergide, or another triptan within the previous 24 hours. It is also contraindicated in patients who have received a monoamine oxidase (MAO)-A inhibitor within the previous 2 weeks. Administration of serotonin 5-HT1 receptor agonists with tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or MAO inhibitors may place patients at risk for serotonin syndrome. This syndrome, with altered mental status, autonomic instability, and hyperreflexia or tremors, may occur within minutes to hours of receiving a new drug or an increase in dose.
Concomitant administration of NSAIDs and methotrexate or lithium may delay the clearance of these drugs and increase the risk for toxicity. The use of NSAIDs with aspirin may reduce the protein binding of aspirin and increase the risk for bleeding. Use with diuretics, angiotensin-converting enzyme inhibitors, or beta-adrenergic blocking agents may decrease their effectiveness. Administration of NSAIDs with warfarin may lead to a greater risk for gastrointestinal bleeding. The clearance of naproxen may be reduced when given with probenecid.
Drug Interactions
Sumatriptan is contraindicated in patients who have received ergotamine-containing drugs, such as dihydroergotamine or methysergide, or another triptan within the previous 24 hours. It is also contraindicated in patients who have received a monoamine oxidase (MAO)-A inhibitor within the previous 2 weeks. Administration of serotonin 5-HT1 receptor agonists with tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or MAO inhibitors may place patients at risk for serotonin syndrome. This syndrome, with altered mental status, autonomic instability, and hyperreflexia or tremors, may occur within minutes to hours of receiving a new drug or an increase in dose.
Concomitant administration of NSAIDs and methotrexate or lithium may delay the clearance of these drugs and increase the risk for toxicity. The use of NSAIDs with aspirin may reduce the protein binding of aspirin and increase the risk for bleeding. Use with diuretics, angiotensin-converting enzyme inhibitors, or beta-adrenergic blocking agents may decrease their effectiveness. Administration of NSAIDs with warfarin may lead to a greater risk for gastrointestinal bleeding. The clearance of naproxen may be reduced when given with probenecid.
Source...